44.210.85.190
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Cataract Surgery

SURF-201 meets primary endpoints for the treatment of post-cataract pain, inflammation

Posted on

SURF-201 (Surface Ophthalmics, Inc) met its primary endpoints of absence of inflammation at day 8 and day 15, according to top-line results from a Phase 2 trial.

In the trial, 91 patients who underwent cataract surgery received twice-daily dosing of SURF-201. The primary endpoints of complete clearance of anterior chamber cells were met at Day 8 (P = 0.01) and Day 15 (P = 0.001). Nearly 90% of patients were pain-free at day 15.

SURF-201 was found to be safe and well-tolerated.

“These results are, to me, extremely promising – showing impressive reduction in pain and inflammation – giving us strong Phase II evidence that SURF-201 has benefits for patients following ocular surgery,” said Richard Lindstrom, MD, in a press release. “With SURF-201, I’m excited to see betamethasone, a potent and safe corticosteroid popular in many countries, advance through clinical trials in the United States. I expect SURF-201 to be a significant new treatment option for the eyecare community, particularly in its unique unit-dose, preservative-free solution with the comforting Klarity vehicle.”

Read the full press release here.

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
Holistic, Targeted, and Individualized Perioperative Care for Cataract Surgery Patients
Aug 04, 2021
Clinician, patient-reported outcome measures important when evaluating cataract surgery outcomes
Apr 19, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-